177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 89 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Why people and culture matter in research August 10, 2021 Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell... July 15, 2025 Utility of Genomic Profiling of cfDNA to Inform Clinical Care for... September 28, 2022 ESMO Breast Cancer Virtual Congress 2021, 5-8 May April 28, 2021 Load more HOT NEWS Let’s Talk About Bubbles Glucose Control Key in Reducing Cancer Risk for People with Type... Two-Time Breast Cancer Warrior Left Devastated After Package Full of Meds... Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer.
